Effects of Low-Dose Spironolactone Combined with Metformin or Either Drug Alone on Insulin Resistance in Patients with Polycystic Ovary Syndrome: A Pilot Study
March 2022
in “
International Journal of Endocrinology
”
TLDR Combining spironolactone with metformin reduces insulin resistance in PCOS better than either drug alone.
This pilot study investigated the effects of low-dose spironolactone combined with metformin versus either drug alone on insulin resistance in patients with polycystic ovary syndrome (PCOS). Conducted at the Third Affiliated Hospital of Guangzhou Medical University, 189 participants were randomized into three groups: metformin, spironolactone, or a combination of both. After 12 weeks, the combination therapy significantly reduced the homeostatic model assessment of insulin resistance (HOMA-IR) more than either monotherapy, with HOMA-IR values of 1.71 in the combined group compared to 1.92 and 2.38 in the metformin and spironolactone groups, respectively. Additionally, the combined therapy resulted in lower total testosterone, free androgen index, and area under the curve-insulin compared to the metformin group, indicating improved outcomes in insulin resistance and androgen levels with the combination treatment.